Adler-Moore J, Lewis RE, Bruggemann RJM, Rijnders BJA, Groll AH, Walsh TJ (2019)
Preclinical safety, tolerability, pharmacokinetics, pharmacodynamics, and antifungal activity of liposomal amphotericin B
Clin Infect Dis 68
pp. S244–S259
Preclinical safety, tolerability, pharmacokinetics, pharmacodynamics, and antifungal activity of liposomal amphotericin B

Candida-parapsilosis, Ohr-Isolat, Reis, 1 Tag, 200-fach, Kontrast

Preclinical safety, tolerability, pharmacokinetics, pharmacodynamics, and antifungal activity of liposomal amphotericin B

Candida tropicalis, Stuhl-Isolat, Reis, -5 Tage,400-fache Vergrößerung. Kontrast

Preclinical safety, tolerability, pharmacokinetics, pharmacodynamics, and antifungal activity of liposomal amphotericin B

Geotrichum candidum, Stuhl-Isolat, Reis, 4 Tage, 200-fache Vergrößerung

Preclinical safety, tolerability, pharmacokinetics, pharmacodynamics, and antifungal activity of liposomal amphotericin B

Saccaromyces cerevisiae, Stuhl-Isolat, SG-Platte Rand, 200-fache Vergrößerung

LAmB; liposomales Amphotericin B; Pharmakodynamik; Pharmakokinetik; präklinisch

Check-ups auf pathogene Hefen

Ursachenmedizinische Untersuchung und Behandlung krankmachender Pilzinfektionen.

KONTAKT